10x Genomics recently priced its initial public offering of 10 million shares of its common stock at $39 per share.

The Pleasanton, California-based single-cell sequencing firm said that underwriters will have the right to purchase up to an additional 1.5 million shares of its common stock at the IPO price.

In a filing with the US Securities and Exchange Commission, 10x said that net proceeds from the offering will be approximately $357.5 million, or approximately $411.9 million if the underwriters exercise their option to purchase additional shares in full.

The shares are expected to begin trading today on the Nasdaq Global Select Market under the symbol "TXG" and the offering is expected to close on Sept. 16, 2019, subject to customary closing conditions.

JP Morgan Securities, Goldman Sachs, and Bank of America Merrill Lynch are acting as lead joint book-running managers for the offering. Cowen is acting as lead manager for the offering. In a preliminary prospectus filed in August, 10x initially said that it was looking to raise up to $100 million in its IPO. Earlier this month, the company upped its offering, noting that it planned to sell up to 9 million shares of stock at a price of $31 to $35 per share, for expected net proceeds of around $271 million.

The company has maintained that it intends to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. It also said that it may use a portion of the net proceeds to acquire businesses, products, or technologies, though noted that it does not currently have agreements or commitments for any material acquisitions.